Loading...
Market
Gene therapy for DFNB9 approved in China by end of 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from Chinese regulatory authorities (e.g., NMPA)
Story
Gene Therapy in China Restores Hearing in Five Deaf Children
Jun 5, 2024, 09:20 AM
A pioneering gene therapy trial in China has successfully restored hearing in both ears of children who were born deaf. The trial, which involved five children, provided a normal copy of a mutated gene, specifically targeting a condition called DFNB9 caused by Otof mutations. This condition accounts for 2-8% of all congenital hearing loss. As a result of the therapy, the children can now listen and dance to music. The study was published in Nature Medicine and The Lancet.
View original story
Similar markets
Yes • 50%
No • 50%
USA • 25%
China • 25%
Germany • 25%
UK • 25%
Continue development • 33%
Discontinue program • 33%
Partner with another company • 33%
Yes • 50%
No • 50%
Successful phase 3 trial by another company • 25%
New regulatory approval • 25%
Major partnership or acquisition • 25%
Another failed trial • 25%
